Ajai Chari, MD

The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.

A look at the quality of life of patients with multiple myeloma who received CAR T-cell therapy.

The panel continues their discussion on infection risk with a look at the immunosuppressive effects of BCMA-targeting bispecifics.

The panel discusses the importance of discussing COVID with patients with multiple myeloma and stressing the need to get vaccinated.

Anne-Marie Jacob shares advice for patients with multiple myeloma receiving teclistamab who are recommended for hospital admission for CRS risk.

Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.

A review of the process of “step-up” doses in teclistamab therapy for multiple myeloma and their use.

A review of the process of giving a patient a dose of teclistamab from start to finish.

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

Nurse Practitioner Kiah Purcell and Registered Nurse Annel Urena explain their role in the diagnosis and education of a patient with multiple myeloma.

Ajai Chari, MD, provides a quick overview of multiple myeloma and patient Anne-Marie Jacob shares the story of her diagnosis.

Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.

Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Centering discussion on the final patient case, experts review the case of a patient with relapsed/refractory multiple myeloma managed with FcRH5-targeting bispecific cevostamab.

Considerations for the integration of GPRC5-targeted therapy into the real-world treatment paradigm of relapsed/refractory multiple myeloma.

Switching focus to GPRC5-targeted bispecific antibody therapy, expert hematologist-oncologists review a patient case of relapsed/refractory MM managed with talquetamab.

Closing out their module on BCMA-targeted therapy in relapsed/refractory MM, panelists highlight the optimal management of ICANS and infections.

Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.

Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.

A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.

“What is more gratifying than people who are alive in complete remission for years?...The therapeutics are so effective and the symptoms of myeloma can be so rapidly reversed. It’s really gratifying.”